Medtech Fundings, September 2015

2 Min Read

Medtech fundings for September 2015 have jumped off at a fast pace and now stand at $457 million, with fundings led by the $300 million IPO of NovoCore, followed by the $100 Series C for CeQur.

Below are the top fundings for the month thus far. Please revisit this post and refresh your browser to see additional fundings during the month.

Medtech fundings for September 2015 have jumped off at a fast pace and now stand at $457 million, with fundings led by the $300 million IPO of NovoCore, followed by the $100 Series C for CeQur.

Below are the top fundings for the month thus far. Please revisit this post and refresh your browser to see additional fundings during the month.

COMPANY, FUNDING PRODUCT/TECHNOLOGY
NovoCure has registered for a $300 million IPO, according to press reports Tumor treating fields, employ low-intensity, alternating fields to treat cancer
CeQur Corp. has raised $100 million in a Series C round of funding according to the company Insulin infusion device for type 2 diabetes
Ivenix, Inc., has raised $42 million in a round of funding according to the company Infusion technologies

For the complete list of medtech fundings in September 2015, see link.

For a historical list of the individual fundings in medtech, by month, since 2009, see link.

Share This Article
Follow:
I serve the interests of medical technology company decision-makers, venture-capitalists, and others with interests in medtech producing worldwide analyses of medical technology markets for my audience of mostly medical technology companies (but also rapidly growing audience of biotech, VC, and other healthcare decision-makers). I have a small staff and go to my industry insiders (or find new ones as needed) to produce detailed, reality-grounded analyses of current and potential markets and opportunities. I am principally interested in those core clinical applications served by medical devices, which are expanding to include biomaterials, drug-device hybrids and other non-device technologies either competing head-on with devices or being integrated with devices in product development. The effort and pain of making every analysis global in scope is rewarded by my audience's loyalty, since in the vast majority of cases they too have global scope in their businesses. Specialties: Business analysis through syndicated reports, and select custom engagements, on medical technology applications and markets in general/abdominal/thoracic surgery, interventional cardiology, cardiothoracic surgery, patient monitoring/management, wound management, cell therapy, tissue engineering, gene therapy, nanotechnology, and others.
Exit mobile version